- Advanced search
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
Coagulation as a patho/physiological process is interpreted as a mechanism for reducing excessive blood loss through the generation of a gel-like clot local to the site of injury. The process involves the activation, adhesion (see Integrins), degranulation and aggregation of platelets, as well as proteins circulating in the plasma. The coagulation cascade involves multiple proteins being converted to more active forms from less active precursors, typically through proteolysis (see Proteases). Listed here are the components of the coagulation cascade targetted by agents in current clinical usage.
1. Cziraky MJ, Spinler SA. (1993) Low-molecular-weight heparins for the treatment of deep-vein thrombosis. Clin Pharm, 12 (12): 892-9. [PMID:8137606]
2. Eriksson BI, Söderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. (1995) A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb. Haemost., 73 (3): 398-401. [PMID:7667822]
3. Friedel HA, Balfour JA. (1994) Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs, 48 (4): 638-60. [PMID:7528134]
4. Gotti R, Parma B, Spelta F, Liverani L. (2013) Affinity capillary electrophoresis in binding study of antithrombin to heparin from different sources. Talanta, 105: 366-71. [PMID:23598032]
5. Holmer E, Söderberg K, Bergqvist D, Lindahl U. (1986) Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis, 16 Suppl 2: 1-7. [PMID:3744129]
6. Kanji S, Devlin JW, Piekos KA, Racine E. (2001) Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis. Pharmacotherapy, 21 (11): 1389-402. [PMID:11714212]
7. Kapur S, Kupfer Y, Tessler S. (2001) Recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 345 (3): 219-20; author reply 220-1. [PMID:11463021]
8. Nakase J, Toribatake Y, Mouri Y, Seki H, Kitaoka K, Tomita K. (2009) Heparin versus danaproid for prevention of venous thromboembolism after hip surgery. J Orthop Surg (Hong Kong), 17 (1): 6-9. [PMID:19398784]
9. Paolucci F, Claviés MC, Donat F, Necciari J. (2002) Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet, 41 Suppl 2: 11-8. [PMID:12383040]
Database page citation:
Blood coagulation components. Accessed on 29/04/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=853.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP, Catterall WA, Cidlowski JA, Davenport AP, Fabbro D, Fan G, McGrath JC, Spedding M, Davies JA and CGTP Collaborators (2015) The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol. 172: 5729-5743.